Psoriasis is a chronic skin disease that causes rashes, scaly patches, and itchiness. There are various types of the condition, among which, plaque psoriasis is the most common . Plaque psoriasis leads to patches of skin becoming raised, dry, and covered in scales. While there is no cure for the condition, certain treatment options can help manage it. Tremfya is one such option that can be used to treat moderate to severe plaque psoriasis.

How Tremfya works
Plaque psoriasis is an autoimmune condition, that is, it is caused by the immune system mistakenly attacking healthy skin cells. Due to this attack, the production of the skin cells increases rapidly, which then causes them to pile up, creating raised patches, called plaques, on the skin’s surface. These plaques can be quite bothersome, as they can cause itchiness and can even be painful. This is why it is important to treat or manage the condition. Here is where Tremfya comes in.

Tremfya is specifically designed to treat plaque psoriasis in adults. It works by preventing a specific protein, called cytokines, from sending inflammatory responses. Once the activity of cytokines is suppressed by Tremfya, the immune system can stop attacking the healthy skin cells. This eventually prevents the development of plaques.

Clinical results of Tremfya
Tremfya conducted a couple of clinical studies which demonstrated promising results.

• In the first study, after 16 weeks of receiving the Tremfya treatment, 70% of the participants noticed that at least 90% of their skin seemed clearer.
• After 48 weeks, in the same study, almost 90% of the participants noticed 90% clearer skin.
• In the second study, 50% of the participants saw their skin had become completely clear after 16 weeks of treatment.

Besides clearing the skin, the studies also showed improvement in other symptoms. After the first 16 weeks of undergoing  Tremfya  treatment, the participants experienced a reduction in symptoms such as itching, pain, burning sensation, and skin tightness. Apart from that, about 80% of the individuals with psoriasis developing on their scalps were found to have an almost clear scalp after 16 weeks of treatment.

FDA approval
FDA is the administrative body responsible for protecting public health by ensuring the safety of foods and treatments. Tremfya is the first treatment of its kind to receive FDA approval for treating adults with moderate to severe plaque psoriasis.  Individuals with psoriasis are at a high risk of developing another inflammatory condition called psoriatic arthritis. This condition can cause swelling, pain, and stiffness in the joints of fingers and toes. Fortunately, Tremfya has been approved by the FDA to treat psoriatic arthritis as well.

Before beginning Tremfya treatment, it is crucial for individuals to consult a doctor and seek their advice.